Jupiter Topco LLC Makes New $4.42 Million Investment in Vericel Corporation $VCEL

Jupiter Topco LLC bought a new stake in Vericel Corporation (NASDAQ:VCEL) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 99,295 shares of the biotechnology company’s stock, valued at approximately $4,417,000. Jupiter Topco LLC owned 0.19% of Vericel as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in VCEL. GAMMA Investing LLC increased its position in Vericel by 17.7% in the second quarter. GAMMA Investing LLC now owns 1,886 shares of the biotechnology company’s stock worth $84,000 after purchasing an additional 283 shares during the period. Osaic Holdings Inc. lifted its position in Vericel by 13.7% during the 2nd quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company’s stock valued at $125,000 after purchasing an additional 353 shares during the period. California State Teachers Retirement System boosted its stake in shares of Vericel by 0.8% in the 2nd quarter. California State Teachers Retirement System now owns 45,404 shares of the biotechnology company’s stock valued at $1,932,000 after purchasing an additional 382 shares during the last quarter. Commonwealth Equity Services LLC boosted its stake in shares of Vericel by 3.6% in the 4th quarter. Commonwealth Equity Services LLC now owns 11,698 shares of the biotechnology company’s stock valued at $421,000 after purchasing an additional 410 shares during the last quarter. Finally, Handelsbanken Fonder AB grew its position in shares of Vericel by 2.2% during the 2nd quarter. Handelsbanken Fonder AB now owns 23,079 shares of the biotechnology company’s stock worth $1,027,000 after buying an additional 500 shares during the period.

Vericel Price Performance

VCEL opened at $39.90 on Tuesday. The company has a market capitalization of $2.04 billion, a price-to-earnings ratio of 84.90 and a beta of 1.06. The business’s 50-day moving average price is $44.90 and its two-hundred day moving average price is $38.38. Vericel Corporation has a 1 year low of $28.95 and a 1 year high of $49.32.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings data on Thursday, July 30th. The biotechnology company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.07. Vericel had a net margin of 7.91% and a return on equity of 6.91%. The business had revenue of $77.46 million for the quarter, compared to analyst estimates of $72.70 million. During the same quarter in the previous year, the firm posted ($0.01) earnings per share. The firm’s revenue for the quarter was up 22.5% on a year-over-year basis. Sell-side analysts anticipate that Vericel Corporation will post 0.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on VCEL. Truist Financial reiterated a “buy” rating and set a $58.00 target price (up from $54.00) on shares of Vericel in a research report on Friday, July 31st. TD Cowen raised their price target on Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of Vericel in a research note on Tuesday, July 28th. Canaccord Genuity Group set a $60.00 price objective on Vericel in a research note on Thursday, July 30th. Finally, Wall Street Zen raised Vericel from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Four analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, Vericel has an average rating of “Moderate Buy” and an average target price of $58.40.

Insider Activity

In related news, insider Sean C. Flynn sold 15,000 shares of the firm’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $45.64, for a total value of $684,600.00. Following the completion of the sale, the insider directly owned 1,647 shares in the company, valued at approximately $75,169.08. This trade represents a 90.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Joseph Anthony Mara, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $44.75, for a total value of $223,750.00. Following the completion of the sale, the chief financial officer directly owned 16,009 shares of the company’s stock, valued at approximately $716,402.75. The trade was a 23.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 52,232 shares of company stock worth $2,304,217. 7.60% of the stock is owned by insiders.

Vericel Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.